TY - JOUR AU - Wang, J. PY - 2020 DA - 2020// TI - Applications of inorganic Nanomaterials in Photothermal therapy based on combinational Cancer treatment JO - Int J Nanomedicine VL - 15 UR - https://doi.org/10.2147/IJN.S239751 DO - 10.2147/IJN.S239751 ID - Wang2020 ER - TY - JOUR AU - Sahin, U. PY - 2017 DA - 2017// TI - Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer JO - Nature VL - 547 UR - https://doi.org/10.1038/nature23003 DO - 10.1038/nature23003 ID - Sahin2017 ER - TY - JOUR AU - Lint, S. PY - 2014 DA - 2014// TI - Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula JO - Cancer Immunol Immunother VL - 63 UR - https://doi.org/10.1007/s00262-014-1558-3 DO - 10.1007/s00262-014-1558-3 ID - Lint2014 ER - TY - JOUR AU - Rosenberg, S. A. AU - Restifo, N. P. PY - 2015 DA - 2015// TI - Adoptive cell transfer as personalized immunotherapy for human cancer JO - Science VL - 348 UR - https://doi.org/10.1126/science.aaa4967 DO - 10.1126/science.aaa4967 ID - Rosenberg2015 ER - TY - JOUR AU - Jeught, K. PY - 2015 DA - 2015// TI - Targeting the tumor microenvironment to enhance antitumor immune responses JO - Oncotarget VL - 6 UR - https://doi.org/10.18632/oncotarget.3204 DO - 10.18632/oncotarget.3204 ID - Jeught2015 ER - TY - JOUR AU - Robert, C. PY - 2020 DA - 2020// TI - A decade of immune-checkpoint inhibitors in cancer therapy JO - Nat Commun VL - 11 UR - https://doi.org/10.1038/s41467-020-17670-y DO - 10.1038/s41467-020-17670-y ID - Robert2020 ER - TY - JOUR AU - Tusup, M. PY - 2019 DA - 2019// TI - Design of in vitro transcribed mRNA vectors for research and therapy JO - Chimia (Aarau) VL - 73 UR - https://doi.org/10.2533/chimia.2019.391 DO - 10.2533/chimia.2019.391 ID - Tusup2019 ER - TY - JOUR AU - Lint, S. PY - 2015 DA - 2015// TI - The ReNAissanCe of mRNA-based cancer therapy JO - Expert Rev Vaccines VL - 14 UR - https://doi.org/10.1586/14760584.2015.957685 DO - 10.1586/14760584.2015.957685 ID - Lint2015 ER - TY - JOUR AU - Pardi, N. AU - Hogan, M. J. AU - Porter, F. W. AU - Weissman, D. PY - 2018 DA - 2018// TI - mRNA vaccines — a new era in vaccinology JO - Nat Rev Drug Discov VL - 17 UR - https://doi.org/10.1038/nrd.2017.243 DO - 10.1038/nrd.2017.243 ID - Pardi2018 ER - TY - JOUR AU - Krupp, G. PY - 1988 DA - 1988// TI - RNA synthesis: strategies for the use of bacteriophage RNA polymerases JO - Gene VL - 72 UR - https://doi.org/10.1016/0378-1119(88)90129-1 DO - 10.1016/0378-1119(88)90129-1 ID - Krupp1988 ER - TY - JOUR AU - Pardi, N. AU - Hogan, M. J. AU - Weissman, D. PY - 2020 DA - 2020// TI - Recent advances in mRNA vaccine technology JO - Curr Opin Immunol VL - 65 UR - https://doi.org/10.1016/j.coi.2020.01.008 DO - 10.1016/j.coi.2020.01.008 ID - Pardi2020 ER - TY - JOUR AU - Verbeke, R. AU - Lentacker, I. AU - Smedt, S. C. AU - Dewitte, H. PY - 2019 DA - 2019// TI - Three decades of messenger RNA vaccine development JO - Nano Today VL - 28 UR - https://doi.org/10.1016/j.nantod.2019.100766 DO - 10.1016/j.nantod.2019.100766 ID - Verbeke2019 ER - TY - JOUR AU - Zhong, Z. PY - 2018 DA - 2018// TI - mRNA therapeutics deliver a hopeful message JO - Nano Today VL - 23 UR - https://doi.org/10.1016/j.nantod.2018.10.005 DO - 10.1016/j.nantod.2018.10.005 ID - Zhong2018 ER - TY - JOUR AU - Devoldere, J. AU - Dewitte, H. AU - Smedt, S. C. AU - Remaut, K. PY - 2016 DA - 2016// TI - Evading innate immunity in nonviral mRNA delivery: don’t shoot the messenger JO - Drug Discov Today VL - 21 UR - https://doi.org/10.1016/j.drudis.2015.07.009 DO - 10.1016/j.drudis.2015.07.009 ID - Devoldere2016 ER - TY - JOUR AU - Desterro, J. AU - Bak-Gordon, P. AU - Carmo-Fonseca, M. PY - 2020 DA - 2020// TI - Targeting mRNA processing as an anticancer strategy JO - Nat Rev Drug Discov VL - 19 UR - https://doi.org/10.1038/s41573-019-0042-3 DO - 10.1038/s41573-019-0042-3 ID - Desterro2020 ER - TY - JOUR AU - Karikó, K. AU - Ni, H. AU - Capodici, J. AU - Lamphier, M. AU - Weissman, D. PY - 2004 DA - 2004// TI - mRNA is an endogenous ligand for toll-like receptor 3 JO - J Biol Chem VL - 279 UR - https://doi.org/10.1074/jbc.M310175200 DO - 10.1074/jbc.M310175200 ID - Karikó2004 ER - TY - JOUR AU - Heil, F. PY - 2004 DA - 2004// TI - Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8 JO - Science VL - 303 UR - https://doi.org/10.1126/science.1093620 DO - 10.1126/science.1093620 ID - Heil2004 ER - TY - JOUR AU - Yoneyama, M. PY - 2004 DA - 2004// TI - The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses JO - Nat Immunol VL - 5 UR - https://doi.org/10.1038/ni1087 DO - 10.1038/ni1087 ID - Yoneyama2004 ER - TY - JOUR AU - Kranz, L. M. PY - 2016 DA - 2016// TI - Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy JO - Nature VL - 534 UR - https://doi.org/10.1038/nature18300 DO - 10.1038/nature18300 ID - Kranz2016 ER - TY - JOUR AU - Anderson, B. R. PY - 2011 DA - 2011// TI - Nucleoside modifications in RNA limit activation of 2′-5′-oligoadenylate synthetase and increase resistance to cleavage by RNase L JO - Nucleic Acids Res VL - 39 UR - https://doi.org/10.1093/nar/gkr586 DO - 10.1093/nar/gkr586 ID - Anderson2011 ER - TY - JOUR AU - Anderson, B. R. PY - 2010 DA - 2010// TI - Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation JO - Nucleic Acids Res VL - 38 UR - https://doi.org/10.1093/nar/gkq347 DO - 10.1093/nar/gkq347 ID - Anderson2010 ER - TY - JOUR AU - Karikó, K. AU - Buckstein, M. AU - Ni, H. AU - Weissman, D. PY - 2005 DA - 2005// TI - Suppression of RNA recognition by toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA JO - Immunity VL - 23 UR - https://doi.org/10.1016/j.immuni.2005.06.008 DO - 10.1016/j.immuni.2005.06.008 ID - Karikó2005 ER - TY - JOUR AU - Andries, O. PY - 2015 DA - 2015// TI - N1-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice JO - J Control Release VL - 217 UR - https://doi.org/10.1016/j.jconrel.2015.08.051 DO - 10.1016/j.jconrel.2015.08.051 ID - Andries2015 ER - TY - JOUR AU - Nelson, J. PY - 2020 DA - 2020// TI - Impact of mRNA chemistry and manufacturing process on innate immune activation JO - Sci Adv VL - 6 UR - https://doi.org/10.1126/sciadv.aaz6893 DO - 10.1126/sciadv.aaz6893 ID - Nelson2020 ER - TY - JOUR AU - Fiegen Durbin, A. AU - Wang, C. AU - Marcotrigiano, J. AU - Gehrke, L. PY - 2016 DA - 2016// TI - RNAs containing modified nucleotides fail to trigger RIG-I conformational changes for innate immune signaling JO - MBio. VL - 7 ID - Fiegen Durbin2016 ER - TY - JOUR AU - Mauger, D. M. PY - 2019 DA - 2019// TI - mRNA structure regulates protein expression through changes in functional half-life JO - Proc Natl Acad Sci U S A. VL - 116 UR - https://doi.org/10.1073/pnas.1908052116 DO - 10.1073/pnas.1908052116 ID - Mauger2019 ER - TY - STD TI - Mauger, D., McFayden Iain & Presnyak, V. Polynucleotide secondary structure. US20200032274A1 (2018). ID - ref27 ER - TY - JOUR AU - Svitkin, Y. V. PY - 2017 DA - 2017// TI - N1-methyl-pseudouridine in mRNA enhances translation through eIF2α-dependent and independent mechanisms by increasing ribosome density JO - Nucleic Acids Res VL - 45 UR - https://doi.org/10.1093/nar/gkx135 DO - 10.1093/nar/gkx135 ID - Svitkin2017 ER - TY - JOUR AU - Broos, K. PY - 2016 DA - 2016// TI - Particle-mediated intravenous delivery of antigen mRNA results in strong antigen-specific T-cell responses despite the induction of type I interferon JO - Mol Ther Nucleic Acids VL - 5 UR - https://doi.org/10.1038/mtna.2016.38 DO - 10.1038/mtna.2016.38 ID - Broos2016 ER - TY - JOUR AU - Karikó, K. AU - Muramatsu, H. AU - Ludwig, J. AU - Weissman, D. PY - 2011 DA - 2011// TI - Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA JO - Nucleic Acids Res VL - 39 UR - https://doi.org/10.1093/nar/gkr695 DO - 10.1093/nar/gkr695 ID - Karikó2011 ER - TY - JOUR AU - Baiersdörfer, M. PY - 2019 DA - 2019// TI - A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA JO - Mol Ther Nucleic Acids VL - 15 UR - https://doi.org/10.1016/j.omtn.2019.02.018 DO - 10.1016/j.omtn.2019.02.018 ID - Baiersdörfer2019 ER - TY - JOUR AU - Foster, J. B. PY - 2019 DA - 2019// TI - Purification of mRNA encoding chimeric antigen receptor is critical for generation of a robust T-cell response JO - Hum Gene Ther VL - 30 UR - https://doi.org/10.1089/hum.2018.145 DO - 10.1089/hum.2018.145 ID - Foster2019 ER - TY - JOUR AU - Thess, A. PY - 2015 DA - 2015// TI - Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals JO - Mol Ther VL - 23 UR - https://doi.org/10.1038/mt.2015.103 DO - 10.1038/mt.2015.103 ID - Thess2015 ER - TY - JOUR AU - Karikó, K. PY - 2008 DA - 2008// TI - Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability JO - Mol Ther VL - 16 UR - https://doi.org/10.1038/mt.2008.200 DO - 10.1038/mt.2008.200 ID - Karikó2008 ER - TY - JOUR AU - Karikó, K. AU - Muramatsu, H. AU - Keller, J. M. AU - Weissman, D. PY - 2012 DA - 2012// TI - Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin JO - Mol Ther VL - 20 UR - https://doi.org/10.1038/mt.2012.7 DO - 10.1038/mt.2012.7 ID - Karikó2012 ER - TY - JOUR AU - Jayaraman, M. PY - 2012 DA - 2012// TI - Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo JO - Angew Chem Int Ed Engl VL - 51 UR - https://doi.org/10.1002/anie.201203263 DO - 10.1002/anie.201203263 ID - Jayaraman2012 ER - TY - JOUR AU - Love, K. T. PY - 2010 DA - 2010// TI - Lipid-like materials for low-dose, in vivo gene silencing JO - Proc Natl Acad Sci U S A VL - 107 UR - https://doi.org/10.1073/pnas.0910603106 DO - 10.1073/pnas.0910603106 ID - Love2010 ER - TY - JOUR AU - Leuschner, F. PY - 2011 DA - 2011// TI - Therapeutic siRNA silencing in inflammatory monocytes in mice JO - Nat Biotechnol VL - 29 UR - https://doi.org/10.1038/nbt.1989 DO - 10.1038/nbt.1989 ID - Leuschner2011 ER - TY - JOUR AU - Akinc, A. PY - 2010 DA - 2010// TI - Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms JO - Mol Ther VL - 18 UR - https://doi.org/10.1038/mt.2010.85 DO - 10.1038/mt.2010.85 ID - Akinc2010 ER - TY - JOUR AU - Akinc, A. PY - 2019 DA - 2019// TI - The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs JO - Nat Nanotechnol VL - 14 UR - https://doi.org/10.1038/s41565-019-0591-y DO - 10.1038/s41565-019-0591-y ID - Akinc2019 ER - TY - JOUR AU - Kauffman, K. J. PY - 2015 DA - 2015// TI - Optimization of lipid nanoparticle formulations for mRNA delivery in vivo with fractional factorial and definitive screening designs JO - Nano Lett VL - 15 UR - https://doi.org/10.1021/acs.nanolett.5b02497 DO - 10.1021/acs.nanolett.5b02497 ID - Kauffman2015 ER - TY - JOUR AU - Sabnis, S. PY - 2018 DA - 2018// TI - A novel amino lipid series for mRNA delivery: improved Endosomal escape and sustained pharmacology and safety in non-human primates JO - Mol Ther VL - 26 UR - https://doi.org/10.1016/j.ymthe.2018.03.010 DO - 10.1016/j.ymthe.2018.03.010 ID - Sabnis2018 ER - TY - JOUR AU - Miao, L. PY - 2020 DA - 2020// TI - Synergistic lipid compositions for albumin receptor mediated delivery of mRNA to the liver JO - Nat Commun VL - 11 UR - https://doi.org/10.1038/s41467-020-16248-y DO - 10.1038/s41467-020-16248-y ID - Miao2020 ER - TY - JOUR AU - Patel, S. PY - 2020 DA - 2020// TI - Naturally-occurring cholesterol analogues in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA JO - Nat Commun VL - 11 UR - https://doi.org/10.1038/s41467-020-14527-2 DO - 10.1038/s41467-020-14527-2 ID - Patel2020 ER - TY - JOUR AU - Nogueira, S. S. PY - 2020 DA - 2020// TI - Polysarcosine-functionalized lipid nanoparticles for therapeutic mRNA delivery JO - ACS Appl Nano Mater VL - 3 UR - https://doi.org/10.1021/acsanm.0c01834 DO - 10.1021/acsanm.0c01834 ID - Nogueira2020 ER - TY - JOUR AU - Stadler, C. R. PY - 2017 DA - 2017// TI - Elimination of large tumors in mice by mRNA-encoded bispecific antibodies JO - Nat Med VL - 23 UR - https://doi.org/10.1038/nm.4356 DO - 10.1038/nm.4356 ID - Stadler2017 ER - TY - JOUR AU - Lai, I. PY - 2018 DA - 2018// TI - Lipid nanoparticles that deliver IL-12 messenger RNA suppress tumorigenesis in MYC oncogene-driven hepatocellular carcinoma JO - J Immunother Cancer VL - 6 UR - https://doi.org/10.1186/s40425-018-0431-x DO - 10.1186/s40425-018-0431-x ID - Lai2018 ER - TY - JOUR AU - Novobrantseva, T. I. PY - 2012 DA - 2012// TI - Systemic RNAi-mediated gene silencing in nonhuman primate and rodent myeloid cells JO - Mol. Ther. Nucleic Acids VL - 1 UR - https://doi.org/10.1038/mtna.2011.3 DO - 10.1038/mtna.2011.3 ID - Novobrantseva2012 ER - TY - JOUR AU - Basha, G. PY - 2011 DA - 2011// TI - Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells JO - Mol Ther VL - 19 UR - https://doi.org/10.1038/mt.2011.190 DO - 10.1038/mt.2011.190 ID - Basha2011 ER - TY - JOUR AU - Parhiz, H. PY - 2018 DA - 2018// TI - PECAM-1 directed re-targeting of exogenous mRNA providing two orders of magnitude enhancement of vascular delivery and expression in lungs independent of apolipoprotein E-mediated uptake JO - J Control Release VL - 291 UR - https://doi.org/10.1016/j.jconrel.2018.10.015 DO - 10.1016/j.jconrel.2018.10.015 ID - Parhiz2018 ER - TY - JOUR AU - Veiga, N. PY - 2018 DA - 2018// TI - Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes JO - Nat Commun VL - 9 UR - https://doi.org/10.1038/s41467-018-06936-1 DO - 10.1038/s41467-018-06936-1 ID - Veiga2018 ER - TY - JOUR AU - Li, Q. PY - 2020 DA - 2020// TI - Engineering Caveolae-targeted lipid nanoparticles to deliver mRNA to the lungs JO - ACS Chem Biol VL - 15 UR - https://doi.org/10.1021/acschembio.0c00003 DO - 10.1021/acschembio.0c00003 ID - Li2020 ER - TY - JOUR AU - Cheng, Q. PY - 2020 DA - 2020// TI - Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR–Cas gene editing JO - Nat Nanotechnol VL - 15 UR - https://doi.org/10.1038/s41565-020-0669-6 DO - 10.1038/s41565-020-0669-6 ID - Cheng2020 ER - TY - STD TI - Hewitt SL, et al. Durable anticancer immunity from intratumoral administration of IL-23, IL-36γ, and OX40L mRNAs. Sci Transl Med. 2019;11(477):eaat9143. ID - ref54 ER - TY - JOUR AU - Hewitt, S. L. PY - 2020 DA - 2020// TI - Intratumoral interleukin-12 mRNA therapy promotes TH1 transformation of the tumor microenvironment JO - Clin Cancer Res. VL - 26 UR - https://doi.org/10.1158/1078-0432.CCR-20-0472 DO - 10.1158/1078-0432.CCR-20-0472 ID - Hewitt2020 ER - TY - JOUR AU - Walsh, E. E. PY - 2020 DA - 2020// TI - Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates JO - N Engl J Med. VL - 383 UR - https://doi.org/10.1056/NEJMoa2027906 DO - 10.1056/NEJMoa2027906 ID - Walsh2020 ER - TY - JOUR AU - Jackson, L. A. PY - 2020 DA - 2020// TI - An mRNA Vaccine against SARS-CoV-2 — Preliminary Report JO - N Engl J Med. VL - 383 UR - https://doi.org/10.1056/NEJMoa2022483 DO - 10.1056/NEJMoa2022483 ID - Jackson2020 ER - TY - JOUR AU - Lecocq, Q. PY - 2019 DA - 2019// TI - Theranostics in immuno-oncology using nanobody derivatives JO - Theranostics VL - 9 UR - https://doi.org/10.7150/thno.34941 DO - 10.7150/thno.34941 ID - Lecocq2019 ER - TY - JOUR AU - Suurs, F. V. AU - Lub-de Hooge, M. N. AU - Vries, E. G. E. AU - Groot, D. J. A. PY - 2019 DA - 2019// TI - A review of bispecific antibodies and antibody constructs in oncology and clinical challenges JO - Pharmacol Ther VL - 201 UR - https://doi.org/10.1016/j.pharmthera.2019.04.006 DO - 10.1016/j.pharmthera.2019.04.006 ID - Suurs2019 ER - TY - JOUR AU - Goswami, S. AU - Wang, W. AU - Arakawa, T. AU - Ohtake, S. PY - 2013 DA - 2013// TI - Developments and challenges for mAb-based therapeutics JO - Antibodies VL - 2 UR - https://doi.org/10.3390/antib2030452 DO - 10.3390/antib2030452 ID - Goswami2013 ER - TY - JOUR AU - Schlake, T. PY - 2019 DA - 2019// TI - mRNA: a novel avenue to antibody therapy? JO - Mol Ther VL - 27 UR - https://doi.org/10.1016/j.ymthe.2019.03.002 DO - 10.1016/j.ymthe.2019.03.002 ID - Schlake2019 ER - TY - JOUR AU - Jäger, V. PY - 2013 DA - 2013// TI - High level transient production of recombinant antibodies and antibody fusion proteins in HEK293 cells JO - BMC Biotechnol VL - 13 UR - https://doi.org/10.1186/1472-6750-13-52 DO - 10.1186/1472-6750-13-52 ID - Jäger2013 ER - TY - JOUR AU - Kong, D. -. H. AU - Kim, M. R. AU - Jang, J. H. AU - Na, H. -. J. AU - Lee, S. PY - 2017 DA - 2017// TI - A review of anti-Angiogenic targets for monoclonal antibody Cancer therapy JO - Int J Mol Sci. VL - 18 UR - https://doi.org/10.3390/ijms18081786 DO - 10.3390/ijms18081786 ID - Kong2017 ER - TY - JOUR AU - Hudis, C. A. PY - 2007 DA - 2007// TI - Trastuzumab--mechanism of action and use in clinical practice JO - N Engl J Med VL - 357 UR - https://doi.org/10.1056/NEJMra043186 DO - 10.1056/NEJMra043186 ID - Hudis2007 ER - TY - JOUR AU - Miguel, D. AU - Lemke, J. AU - Anel, A. AU - Walczak, H. AU - Martinez-Lostao, L. PY - 2016 DA - 2016// TI - Onto better TRAILs for cancer treatment JO - Cell Death Differ VL - 23 UR - https://doi.org/10.1038/cdd.2015.174 DO - 10.1038/cdd.2015.174 ID - Miguel2016 ER - TY - JOUR AU - Thomas, A. AU - Teicher, B. A. AU - Hassan, R. PY - 2016 DA - 2016// TI - Antibody-drug conjugates for cancer therapy JO - Lancet Oncol VL - 17 UR - https://doi.org/10.1016/S1470-2045(16)30030-4 DO - 10.1016/S1470-2045(16)30030-4 ID - Thomas2016 ER - TY - JOUR AU - Kellner, C. AU - Otte, A. AU - Cappuzzello, E. AU - Klausz, K. AU - Peipp, M. PY - 2017 DA - 2017// TI - Modulating cytotoxic effector functions by fc engineering to improve Cancer therapy JO - Transfus Med Hemother VL - 44 UR - https://doi.org/10.1159/000479980 DO - 10.1159/000479980 ID - Kellner2017 ER - TY - JOUR AU - Harjunpaa AU - Junnikkala AU - Meri PY - 2000 DA - 2000// TI - Rituximab (Anti-CD20) Therapy of B-Cell Lymphomas: Direct Complement Killing is Superior to Cellular Effector Mechanisms JO - Scand J Immunol VL - 51 UR - https://doi.org/10.1046/j.1365-3083.2000.00745.x DO - 10.1046/j.1365-3083.2000.00745.x ID - Harjunpaa2000 ER - TY - JOUR AU - Thran, M. PY - 2017 DA - 2017// TI - mRNA mediates passive vaccination against infectious agents, toxins, and tumors JO - EMBO Mol Med. VL - 9 UR - https://doi.org/10.15252/emmm.201707678 DO - 10.15252/emmm.201707678 ID - Thran2017 ER - TY - JOUR AU - Slaney, C. Y. AU - Wang, P. AU - Darcy, P. K. AU - Kershaw, M. H. PY - 2018 DA - 2018// TI - CARs versus BiTEs: a comparison between T cell-redirection strategies for Cancer treatment JO - Cancer Discov VL - 8 UR - https://doi.org/10.1158/2159-8290.CD-18-0297 DO - 10.1158/2159-8290.CD-18-0297 ID - Slaney2018 ER - TY - JOUR AU - Suryadevara, C. M. PY - 2015 DA - 2015// TI - Are BiTEs the ‘missing link’ in cancer therapy? JO - Oncoimmunology VL - 4 UR - https://doi.org/10.1080/2162402X.2015.1008339 DO - 10.1080/2162402X.2015.1008339 ID - Suryadevara2015 ER - TY - JOUR AU - Ribas, A. AU - Wolchok, J. D. PY - 2018 DA - 2018// TI - Cancer immunotherapy using checkpoint blockade JO - Science VL - 359 UR - https://doi.org/10.1126/science.aar4060 DO - 10.1126/science.aar4060 ID - Ribas2018 ER - TY - JOUR AU - Couzin-Frankel, J. PY - 2013 DA - 2013// TI - Breakthrough of the year 2013. Cancer Immunotherapy JO - Science VL - 342 UR - https://doi.org/10.1126/science.342.6165.1432 DO - 10.1126/science.342.6165.1432 ID - Couzin-Frankel2013 ER - TY - JOUR AU - Broos, K. PY - 2019 DA - 2019// TI - Single domain antibody-mediated blockade of programmed death-ligand 1 on dendritic cells enhances CD8 T-cell activation and cytokine production JO - Vaccines. VL - 7 UR - https://doi.org/10.3390/vaccines7030085 DO - 10.3390/vaccines7030085 ID - Broos2019 ER - TY - JOUR AU - Broos, K. PY - 2019 DA - 2019// TI - Evaluating a single domain antibody targeting human PD-L1 as a nuclear imaging and therapeutic agent JO - Cancers (Basel). VL - 11 UR - https://doi.org/10.3390/cancers11060872 DO - 10.3390/cancers11060872 ID - Broos2019 ER - TY - JOUR AU - Wan, R. PY - 2018 DA - 2018// TI - Screening and antitumor effect of an anti-CTLA-4 nanobody JO - Oncol Rep VL - 39 ID - Wan2018 ER - TY - JOUR AU - Ingram, J. R. PY - 2018 DA - 2018// TI - Anti-CTLA-4 therapy requires an fc domain for efficacy JO - Proc Natl Acad Sci U S A VL - 115 UR - https://doi.org/10.1073/pnas.1801524115 DO - 10.1073/pnas.1801524115 ID - Ingram2018 ER - TY - JOUR AU - Ramsay, A. G. PY - 2013 DA - 2013// TI - Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity JO - Br J Haematol VL - 162 UR - https://doi.org/10.1111/bjh.12380 DO - 10.1111/bjh.12380 ID - Ramsay2013 ER - TY - JOUR AU - Pruitt, S. K. PY - 2011 DA - 2011// TI - Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells JO - Eur J Immunol VL - 41 UR - https://doi.org/10.1002/eji.201141383 DO - 10.1002/eji.201141383 ID - Pruitt2011 ER - TY - JOUR AU - Hoecke, L. PY - 2018 DA - 2018// TI - Treatment with mRNA coding for the necroptosis mediator MLKL induces antitumor immunity directed against neo-epitopes JO - Nat Commun VL - 9 UR - https://doi.org/10.1038/s41467-018-05979-8 DO - 10.1038/s41467-018-05979-8 ID - Hoecke2018 ER - TY - JOUR AU - Bonehill, A. PY - 2008 DA - 2008// TI - Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA JO - Mol Ther. VL - 16 UR - https://doi.org/10.1038/mt.2008.77 DO - 10.1038/mt.2008.77 ID - Bonehill2008 ER - TY - JOUR AU - Bonehill, A. PY - 2009 DA - 2009// TI - Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients JO - Clin Cancer Res VL - 15 UR - https://doi.org/10.1158/1078-0432.CCR-08-2982 DO - 10.1158/1078-0432.CCR-08-2982 ID - Bonehill2009 ER - TY - JOUR AU - Wilgenhof, S. PY - 2011 DA - 2011// TI - Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma JO - J Immunother VL - 34 UR - https://doi.org/10.1097/CJI.0b013e31821dcb31 DO - 10.1097/CJI.0b013e31821dcb31 ID - Wilgenhof2011 ER - TY - JOUR AU - Wilgenhof, S. PY - 2013 DA - 2013// TI - A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients JO - Ann Oncol Off J Eur Soc Med Oncol VL - 24 UR - https://doi.org/10.1093/annonc/mdt245 DO - 10.1093/annonc/mdt245 ID - Wilgenhof2013 ER - TY - JOUR AU - Ren, J. AU - Chen, X. AU - Chen, Z. J. PY - 2014 DA - 2014// TI - IKKβ is an IRF5 kinase that instigates inflammation JO - Proc Natl Acad Sci U S A VL - 111 UR - https://doi.org/10.1073/pnas.1418516111 DO - 10.1073/pnas.1418516111 ID - Ren2014 ER - TY - JOUR AU - Jeught, K. PY - 2014 DA - 2014// TI - Intratumoral administration of mRNA encoding a fusokine consisting of IFN-β and the ectodomain of the TGF-β receptor II potentiates antitumor immunity JO - Oncotarget VL - 5 UR - https://doi.org/10.18632/oncotarget.2463 DO - 10.18632/oncotarget.2463 ID - Jeught2014 ER - TY - JOUR AU - Jain, R. PY - 2018 DA - 2018// TI - MicroRNAs enable mRNA therapeutics to selectively program Cancer cells to self-destruct JO - Nucleic Acid Ther VL - 28 UR - https://doi.org/10.1089/nat.2018.0734 DO - 10.1089/nat.2018.0734 ID - Jain2018 ER - TY - JOUR AU - Li, H. AU - Zhu, H. AU - Xu, C. J. AU - Yuan, J. PY - 1998 DA - 1998// TI - Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis JO - Cell VL - 94 UR - https://doi.org/10.1016/S0092-8674(00)81590-1 DO - 10.1016/S0092-8674(00)81590-1 ID - Li1998 ER - TY - JOUR AU - Gabrilovich, D. I. AU - Ishida, T. AU - Nadaf, S. AU - Ohm, J. E. AU - Carbone, D. P. PY - 1999 DA - 1999// TI - Antibodies to vascular endothelial growth factor enhance the efficacy of Cancer immunotherapy by improving endogenous dendritic cell function JO - Clin Cancer Res VL - 3 ID - Gabrilovich1999 ER - TY - JOUR AU - Liu, Q. PY - 2009 DA - 2009// TI - Tumor-educated CD11bhighIalow regulatory dendritic cells suppress T cell response through arginase I JO - J Immunol VL - 182 UR - https://doi.org/10.4049/jimmunol.0803926 DO - 10.4049/jimmunol.0803926 ID - Liu2009 ER - TY - JOUR AU - Ruffel, B. PY - 2014 DA - 2014// TI - Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells JO - Cancer Cell. VL - 26 UR - https://doi.org/10.1016/j.ccell.2014.09.006 DO - 10.1016/j.ccell.2014.09.006 ID - Ruffel2014 ER - TY - JOUR AU - Laoui, D. PY - 2016 DA - 2016// TI - The tumour microenvironment harbours ontogenically distinct dendritic cell populations with opposing effects on tumour immunity JO - Nat Commun VL - 7 UR - https://doi.org/10.1038/ncomms13720 DO - 10.1038/ncomms13720 ID - Laoui2016 ER - TY - JOUR AU - Pyfferoen, L. PY - 2017 DA - 2017// TI - The transcriptome of lung tumor-infiltrating dendritic cells reveals a tumor-supporting phenotype and a microRNA signature with negative impact on clinical outcome JO - Oncoimmunology VL - 6 UR - https://doi.org/10.1080/2162402X.2016.1253655 DO - 10.1080/2162402X.2016.1253655 ID - Pyfferoen2017 ER - TY - JOUR AU - Lint, S. PY - 2016 DA - 2016// TI - Intratumoral delivery of TriMix mRNA results in T-cell activation by cross-presenting dendritic cells JO - Cancer Immunol Res VL - 4 UR - https://doi.org/10.1158/2326-6066.CIR-15-0163 DO - 10.1158/2326-6066.CIR-15-0163 ID - Lint2016 ER - TY - JOUR AU - Haabeth, O. A. W. PY - 2019 DA - 2019// TI - Local delivery of OX40L, CD80, and CD86 mRNA kindles global anticancer immunity JO - Cancer Res VL - 79 UR - https://doi.org/10.1158/0008-5472.CAN-18-2867 DO - 10.1158/0008-5472.CAN-18-2867 ID - Haabeth2019 ER - TY - JOUR AU - Munn, D. H. AU - Bronte, V. PY - 2016 DA - 2016// TI - Immune suppressive mechanisms in the tumor microenvironment JO - Curr Opin Immunol VL - 39 UR - https://doi.org/10.1016/j.coi.2015.10.009 DO - 10.1016/j.coi.2015.10.009 ID - Munn2016 ER - TY - STD TI - Van Lint, S. et al. Priming of Cytotoxic T Lymphocyte Responses by Dendritic Cells: Induction of Potent anti-tumor Immune Responses. in Horizons in Cancer Research (ed. Watanabe, H. S.) 1–32 (Nova Biomedical, 2013). ID - ref97 ER - TY - JOUR AU - Vlaeminck, Y. PY - 2020 DA - 2020// TI - Targeting Neuropilin-1 with Nanobodies reduces colorectal carcinoma development JO - Cancers (Basel) VL - 12 UR - https://doi.org/10.3390/cancers12123582 DO - 10.3390/cancers12123582 ID - Vlaeminck2020 ER - TY - JOUR AU - Bolli, E. PY - 2019 DA - 2019// TI - Stromal-targeting radioimmunotherapy mitigates the progression of therapy-resistant tumors JO - J Control Release VL - 314 UR - https://doi.org/10.1016/j.jconrel.2019.10.024 DO - 10.1016/j.jconrel.2019.10.024 ID - Bolli2019 ER - TY - JOUR AU - Awad, R. M. AU - Vlaeminck, Y. AU - Maebe, J. AU - Goyvaerts, C. AU - Breckpot, K. PY - 2018 DA - 2018// TI - Turn Back the TIMe: targeting tumor infiltrating myeloid cells to revert Cancer progression JO - Front Immunol VL - 9 UR - https://doi.org/10.3389/fimmu.2018.01977 DO - 10.3389/fimmu.2018.01977 ID - Awad2018 ER - TY - JOUR AU - Vlaeminck, Y. AU - González-Rascón, A. AU - Goyvaerts, C. AU - Breckpot, K. PY - 2016 DA - 2016// TI - Cancer-associated myeloid regulatory cells JO - Front Immunol VL - 7 UR - https://doi.org/10.3389/fimmu.2016.00113 DO - 10.3389/fimmu.2016.00113 ID - Vlaeminck2016 ER - TY - JOUR AU - Zhang, F. PY - 2019 DA - 2019// TI - Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers JO - Nat Commun VL - 10 UR - https://doi.org/10.1038/s41467-019-11911-5 DO - 10.1038/s41467-019-11911-5 ID - Zhang2019 ER - TY - JOUR AU - Seif, M. AU - Hoppstädter, J. AU - Breinig, F. AU - Kiemer, A. K. PY - 2017 DA - 2017// TI - Yeast-mediated mRNA delivery polarizes immuno-suppressive macrophages towards an immuno-stimulatory phenotype JO - Eur J Pharm Biopharm VL - 117 UR - https://doi.org/10.1016/j.ejpb.2017.03.008 DO - 10.1016/j.ejpb.2017.03.008 ID - Seif2017 ER - TY - JOUR AU - Krausgruber, T. PY - 2011 DA - 2011// TI - IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses JO - Nat Immunol VL - 12 UR - https://doi.org/10.1038/ni.1990 DO - 10.1038/ni.1990 ID - Krausgruber2011 ER - TY - JOUR AU - Kraman, M. PY - 2010 DA - 2010// TI - Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-α JO - Science VL - 330 UR - https://doi.org/10.1126/science.1195300 DO - 10.1126/science.1195300 ID - Kraman2010 ER - TY - JOUR AU - Wang, L. C. S. PY - 2014 DA - 2014// TI - Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity JO - Cancer Immunol Res. VL - 2 UR - https://doi.org/10.1158/2326-6066.CIR-13-0027 DO - 10.1158/2326-6066.CIR-13-0027 ID - Wang2014 ER - TY - JOUR AU - Santana-Viera, L. AU - Ibba, M. L. AU - Rotoli, D. AU - Catuogno, S. AU - Esposito, C. L. PY - 2020 DA - 2020// TI - Emerging therapeutic RNAs for the targeting of cancer associated fibroblasts JO - Cancers. VL - 12 UR - https://doi.org/10.3390/cancers12061365 DO - 10.3390/cancers12061365 ID - Santana-Viera2020 ER - TY - JOUR AU - Miao, L. PY - 2017 DA - 2017// TI - Targeting tumor-associated fibroblasts for therapeutic delivery in desmoplastic tumors JO - Cancer Res VL - 77 UR - https://doi.org/10.1158/0008-5472.CAN-16-0866 DO - 10.1158/0008-5472.CAN-16-0866 ID - Miao2017 ER - TY - JOUR AU - Miao, L. PY - 2017 DA - 2017// TI - Transient and local expression of chemokine and immune checkpoint traps to treat pancreatic Cancer JO - ACS Nano VL - 11 UR - https://doi.org/10.1021/acsnano.7b01786 DO - 10.1021/acsnano.7b01786 ID - Miao2017 ER - TY - JOUR AU - Goodwin, T. J. PY - 2017 DA - 2017// TI - Liver specific gene immunotherapies resolve immune suppressive ectopic lymphoid structures of liver metastases and prolong survival JO - Biomaterials VL - 141 UR - https://doi.org/10.1016/j.biomaterials.2017.07.007 DO - 10.1016/j.biomaterials.2017.07.007 ID - Goodwin2017 ER - TY - JOUR AU - Mumm, J. B. AU - Oft, M. PY - 2008 DA - 2008// TI - Cytokine-based transformation of immune surveillance into tumor-promoting inflammation JO - Oncogene VL - 27 UR - https://doi.org/10.1038/onc.2008.275 DO - 10.1038/onc.2008.275 ID - Mumm2008 ER - TY - JOUR AU - Rosenberg, S. A. PY - 1987 DA - 1987// TI - A Progress report on the treatment of 157 patients with advanced Cancer using Lymphokine-activated killer cells and Interleukin-2 or high-dose Interleukin-2 alone JO - N Engl J Med VL - 316 UR - https://doi.org/10.1056/NEJM198704093161501 DO - 10.1056/NEJM198704093161501 ID - Rosenberg1987 ER - TY - JOUR AU - Malkova, N. V. PY - 2020 DA - 2020// TI - Abstract 4451: Combination of local mRNA immunotherapy with systemic immune checkpoint blockade demonstrates anti-tumor activity across a diverse range of preclinical syngeneic tumor models JO - Immunology VL - 80 ID - Malkova2020 ER - TY - JOUR AU - Kim, S. PY - 2008 DA - 2008// TI - Systemic blockade of transforming growth factor- signaling augments the efficacy of Immunogene therapy JO - Cancer Res VL - 68 UR - https://doi.org/10.1158/0008-5472.CAN-08-1494 DO - 10.1158/0008-5472.CAN-08-1494 ID - Kim2008 ER - TY - JOUR AU - Zídek, Z. AU - Anzenbacher, P. AU - Kmoníčková, E. PY - 2009 DA - 2009// TI - Current status and challenges of cytokine pharmacology JO - Br J Pharmacol VL - 157 UR - https://doi.org/10.1111/j.1476-5381.2009.00206.x DO - 10.1111/j.1476-5381.2009.00206.x ID - Zídek2009 ER - TY - JOUR AU - Milling, L. AU - Zhang, Y. AU - Irvine, D. J. PY - 2017 DA - 2017// TI - Delivering safer immunotherapies for cancer JO - Adv Drug Deliv Rev VL - 114 UR - https://doi.org/10.1016/j.addr.2017.05.011 DO - 10.1016/j.addr.2017.05.011 ID - Milling2017 ER - TY - JOUR AU - Trinchieri, G. PY - 2003 DA - 2003// TI - Interleukin-12 and the regulation of innate resistance and adaptive immunity JO - Nat Rev Immunol VL - 3 UR - https://doi.org/10.1038/nri1001 DO - 10.1038/nri1001 ID - Trinchieri2003 ER - TY - JOUR AU - Eyquem, J. PY - 2017 DA - 2017// TI - Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection JO - Nature VL - 543 UR - https://doi.org/10.1038/nature21405 DO - 10.1038/nature21405 ID - Eyquem2017 ER - TY - JOUR AU - Brentjens, R. AU - Yeh, R. AU - Bernal, Y. AU - Riviere, I. AU - Sadelain, M. PY - 2010 DA - 2010// TI - Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial JO - Mol Ther VL - 18 UR - https://doi.org/10.1038/mt.2010.31 DO - 10.1038/mt.2010.31 ID - Brentjens2010 ER - TY - JOUR AU - Rabinovich, P. M. PY - 2009 DA - 2009// TI - Chimeric receptor mRNA transfection as a tool to generate antineoplastic lymphocytes JO - Hum Gene Ther VL - 20 UR - https://doi.org/10.1089/hum.2008.068 DO - 10.1089/hum.2008.068 ID - Rabinovich2009 ER - TY - JOUR AU - Zhao, Y. PY - 2010 DA - 2010// TI - Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor JO - Cancer Res VL - 70 UR - https://doi.org/10.1158/0008-5472.CAN-10-2880 DO - 10.1158/0008-5472.CAN-10-2880 ID - Zhao2010 ER - TY - JOUR AU - Morgan, R. A. PY - 2010 DA - 2010// TI - Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2 JO - Mol Ther VL - 18 UR - https://doi.org/10.1038/mt.2010.24 DO - 10.1038/mt.2010.24 ID - Morgan2010 ER - TY - JOUR AU - Maus, M. V. PY - 2013 DA - 2013// TI - T cells expressing chimeric antigen receptors can cause anaphylaxis in humans JO - Cancer Immunol Res VL - 1 UR - https://doi.org/10.1158/2326-6066.CIR-13-0006 DO - 10.1158/2326-6066.CIR-13-0006 ID - Maus2013 ER - TY - JOUR AU - Weinstein-Marom, H. PY - 2016 DA - 2016// TI - Membrane-attached cytokines expressed by mRNA electroporation act as potent T-cell adjuvants JO - J Immunother VL - 39 UR - https://doi.org/10.1097/CJI.0000000000000109 DO - 10.1097/CJI.0000000000000109 ID - Weinstein-Marom2016 ER - TY - JOUR AU - Pohl-Guimarães, F. PY - 2019 DA - 2019// TI - RNA-modified T cells mediate effective delivery of Immunomodulatory cytokines to brain tumors JO - Mol Ther VL - 27 UR - https://doi.org/10.1016/j.ymthe.2018.10.007 DO - 10.1016/j.ymthe.2018.10.007 ID - Pohl-Guimarães2019 ER - TY - JOUR AU - Foster, J. B. AU - Barrett, D. M. AU - Karikó, K. PY - 2019 DA - 2019// TI - The emerging role of in vitro-transcribed mRNA in adoptive T cell immunotherapy JO - Mol Ther VL - 27 UR - https://doi.org/10.1016/j.ymthe.2019.01.018 DO - 10.1016/j.ymthe.2019.01.018 ID - Foster2019 ER - TY - JOUR PY - 2020 DA - 2020// JO - Nat Biotechnol. VL - 38 UR - https://doi.org/10.1038/s41587-020-0676-z DO - 10.1038/s41587-020-0676-z ID - ref127 ER - TY - JOUR AU - Pfeiffer, A. PY - 2018 DA - 2018// TI - In vivo generation of human CD 19- CAR T cells results in B-cell depletion and signs of cytokine release syndrome JO - EMBO Mol Med. VL - 10 UR - https://doi.org/10.15252/emmm.201809158 DO - 10.15252/emmm.201809158 ID - Pfeiffer2018 ER - TY - JOUR AU - Agarwal, S. AU - Weidner, T. AU - Thalheimer, F. B. AU - Buchholz, C. J. PY - 2019 DA - 2019// TI - In vivo generated human CAR T cells eradicate tumor cells JO - Oncoimmunology VL - 8 UR - https://doi.org/10.1080/2162402X.2019.1671761 DO - 10.1080/2162402X.2019.1671761 ID - Agarwal2019 ER - TY - JOUR AU - Smith, T. T. PY - 2017 DA - 2017// TI - In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers JO - Nat Nanotechnol VL - 12 UR - https://doi.org/10.1038/nnano.2017.57 DO - 10.1038/nnano.2017.57 ID - Smith2017 ER - TY - JOUR AU - McKinlay, C. J. AU - Benner, N. L. AU - Haabeth, O. A. AU - Waymouth, R. M. AU - Wender, P. A. PY - 2018 DA - 2018// TI - Enhanced mRNA delivery into lymphocytes enabled by lipid-varied libraries of charge-altering releasable transporters JO - Proc Natl Acad Sci U S A VL - 115 UR - https://doi.org/10.1073/pnas.1805358115 DO - 10.1073/pnas.1805358115 ID - McKinlay2018 ER - TY - JOUR AU - Chen, F. AU - Cai, W. PY - 2014 DA - 2014// TI - Tumor vasculature targeting: a generally applicable approach for functionalized nanomaterials JO - Small VL - 10 UR - https://doi.org/10.1002/smll.201303627 DO - 10.1002/smll.201303627 ID - Chen2014 ER - TY - JOUR AU - Ma, F. PY - 2020 DA - 2020// TI - Neurotransmitter-derived lipidoids (NT-lipidoids) for enhanced brain delivery through intravenous injection JO - Sci Adv VL - 6 UR - https://doi.org/10.1126/sciadv.abb4429 DO - 10.1126/sciadv.abb4429 ID - Ma2020 ER - TY - JOUR AU - Tang, J. AU - Shalabi, A. AU - Hubbard-Lucey, V. M. PY - 2018 DA - 2018// TI - Comprehensive analysis of the clinical immuno-oncology landscape JO - Ann Oncol VL - 29 UR - https://doi.org/10.1093/annonc/mdx755 DO - 10.1093/annonc/mdx755 ID - Tang2018 ER - TY - JOUR AU - Barlesi, F. PY - 2020 DA - 2020// TI - LBA53 precision immuno-oncology for advanced non-small cell lung cancer (NSCLC) patients (pts) treated with PD1/L1 immune checkpoint inhibitors (ICIs): a first analysis of the PIONeeR study JO - Ann Oncol VL - 31 UR - https://doi.org/10.1016/j.annonc.2020.08.2286 DO - 10.1016/j.annonc.2020.08.2286 ID - Barlesi2020 ER - TY - JOUR AU - Ciccolini, J. AU - Benzekry, S. AU - Barlesi, F. PY - 2020 DA - 2020// TI - Deciphering the response and resistance to immune-checkpoint inhibitors in lung cancer with artificial intelligence-based analysis: when PIONeeR meets QUANTIC JO - Br J Cancer VL - 123 UR - https://doi.org/10.1038/s41416-020-0918-3 DO - 10.1038/s41416-020-0918-3 ID - Ciccolini2020 ER -